Atherosclerosis in Systemic Lupus Erythematosus Ã¢ÂÂ Epidemiology, Risk Factors, Subclinical Assessment and Future StudyBarry J Sheane1, Murray B Urowitz2* and Dafna D Gladman3
2University of Toronto, Centre for Prognosis Studies in The Rheumatic Diseases and Lupus Clinic, Toronto Western Hospital, Senior Scientist, Toronto Western Research Institute, Toronto, Ontario, Canada
3University of Toronto, Centre for Prognosis Studies in The Rheumatic Diseases and Lupus Clinic, Toronto Western Hospital, Senior Scientist, Toronto Western Research Institute, Toronto, Ontario, Canada
- *Corresponding Author:
- Dr. Murray Urowitz
Toronto Western Hospital
399 Bathurst Street
1E-410B, Toronto Ontario, Canada
E-mail: [email protected]
Received Date: March 06, 2013; Accepted Date: May 15, 2013; Published Date: May 27, 2013
Citation: Sheane BJ, Urowitz MB, Gladman DD (2013) Atherosclerosis in Systemic Lupus Erythematosus – Epidemiology, Risk Factors, Subclinical Assessment and Future Study. Rheumatol Curr Res S5:004. doi: 10.4172/2161-1149.S5-004
Copyright: © 2013 Sheane BJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Over the last 40 years, it has become established that patients with Systemic Lupus Erythematosus (SLE) have a greater risk of atherosclerosis and related events compared with the general population of similar age and sex. While the precise mechanisms that cause accelerated atherosclerosis in SLE remain undetermined, much evidence from inceptional and prospective longitudinal studies suggests a role for traditional cardiovascular disease and lupusspecific risk factors, systemic inflammation and lupus-directed therapies. This review will summarize much of the important knowledge available in the medical literature on this topic.